Papillary thyroid carcinoma
Conditions
Interventions
experimental group:Gasless Transaxillary Posterial Endoscopic Thyroidectomy and Ipsilateral Central Lymph Node Dissection
control group:Conventional Open Thyroidectomy and Ipsilateral Central Lymph Node Dissection
Sponsors
Nanfang Hospital of Southern Medical University
Eligibility
Sex/Gender
All
Age
18 Years to 70 Years
Inclusion criteria
Inclusion criteria: 1. The patient's informed consent; 2. Aged > 18 years and < 70 years; 3. Papillary thyroid carcinoma (Bethesda grade V-VI) was pathologically diagnosed by fine needle aspiration biopsy of the primary thyroid tumor before surgery; 4. Color Doppler TI-RADS 4c-5 of primary thyroid tumor; 5. The preoperative clinical staging is T1, N0-1a, M0 (see diagnostic criteria for details; according to AJCC-8th TNM tumor staging); 6. It is expected that R0 surgical results can be obtained by performing single thyroid lobectomy and isthmus resection + ipsilateral central lymph node dissection; 7. Preoperative ASA score I-III.
Exclusion criteria
Exclusion criteria: 1. Pregnant or lactating patients; 2. Suffering from serious mental illness; 3. Preoperative imaging examinations suggest that the tumor is located in the thyroid isthmus or involves bilateral lobes; 4. Preoperative imaging examinations suggest the possibility of cervical lateral lymph node or distant metastasis; 5. Hashimoto's thyroiditis combined with hyperthyroidism or abnormal thyroid function; 6. History of neck surgery; 7. History of thyroid surgery (including ablation therapy for thyroid nodules); 8. Family history of thyroid cancer; 9. History of childhood ionizing radiation exposure; 10. History of other malignant diseases within 5 years; 11. A history of unstable angina or myocardial infarction within 6 months; 12. History of cerebral infarction or cerebral hemorrhage within 6 months; 13. History of continuous systemic corticosteroid therapy within 1 month; 14. Concurrent surgical treatment of other diseases is required; 15. Patients who are judged by the investigator to be unsuitable to participate in this trial.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Early complication rate;Life quality score; | — |
Secondary
| Measure | Time frame |
|---|---|
| The number of dissected lymph nodes;The volumn of residual gland;3-year recurrence rate;Operation duration;Blood loss;Hospital stays;Hospitalization expense;Inflammatory and immune response; | — |
Countries
China
Contacts
Public ContactLei Shangtong
Nanfang Hospital of Southern Medical University
Outcome results
None listed